Evidence for treatment with anti-PD-1 antibody for thymic cancer: how to identify patients most likely to benefit

Kentaro Suina, Takehito Shukuya


Thymic epithelial tumor (TET) is a rare disease with an annual incidence of 0.15 cases per 100,000 people (1). Accordingly, thymic carcinoma (TC) accounts for approximately 14% of all such cases (2). However, developing treatments for TC is fraught with many practical challenges, whereas critical medical needs remain unmet.